dasatinib alvogen 100 mg tabletki powlekane
alvogen pharma trading europe eood - dasatinibum - tabletki powlekane - 100 mg
dasatinib alvogen 140 mg tabletki powlekane
alvogen pharma trading europe eood - dasatinibum - tabletki powlekane - 140 mg
sorafenib alvogen 200 mg tabletki powlekane
alvogen pharma trading europe eood - sorafenibi tosilas - tabletki powlekane - 200 mg
daruph 55 mg tabletki powlekane
zentiva, k.s. - dasatinibum - tabletki powlekane - 55 mg
daruph 111 mg tabletki powlekane
zentiva, k.s. - dasatinibum - tabletki powlekane - 111 mg
daruph 16 mg tabletki powlekane
zentiva, k.s. - dasatinibum - tabletki powlekane - 16 mg
daruph 40 mg tabletki powlekane
zentiva, k.s. - dasatinibum - tabletki powlekane - 40 mg
daruph 79 mg tabletki powlekane
zentiva, k.s. - dasatinibum - tabletki powlekane - 79 mg
daruph 63 mg tabletki powlekane
zentiva, k.s. - dasatinibum - tabletki powlekane - 63 mg
lytgobi
taiho pharma netherlands b.v. - futibatinib - cholangiocarcinoma - środki agenci - lytgobi monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (fgfr2) fusion or rearrangement that have progressed after at least one prior line of systemic therapy.